2017
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
Verguet S, Riumallo-Herl C, Gomez GB, Menzies NA, Houben RMGJ, Sumner T, Lalli M, White RG, Salomon JA, Cohen T, Foster N, Chatterjee S, Sweeney S, Baena IG, Lönnroth K, Weil DE, Vassall A. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health 2017, 5: e1123-e1132. PMID: 29025634, PMCID: PMC5640802, DOI: 10.1016/s2214-109x(17)30341-8.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisEnd TB StrategyTuberculosis servicesCatastrophic costsTB StrategyDrug-sensitive tuberculosisCatastrophic financial burdenAnnual household incomeTuberculosis careTuberculosis controlEconomic burdenTuberculosisIntervention effectsMelinda Gates FoundationHousehold incomeIndirect costsFinancial burdenExpansion of accessPatientsTotal annual household incomeTreatmentCareGates FoundationBurdenIntervention scenarios
2016
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health 2016, 4: e816-e826. PMID: 27720689, PMCID: PMC5527122, DOI: 10.1016/s2214-109x(16)30265-0.Peer-Reviewed Original ResearchMeSH KeywordsChinaCost-Benefit AnalysisDelivery of Health CareForecastingGoalsHealth Care CostsHealth ExpendituresHealth PolicyHealth ResourcesHealth Services AccessibilityHealth Services Needs and DemandHumansIndiaModels, TheoreticalPatient Acceptance of Health CareQuality-Adjusted Life YearsSouth AfricaTuberculosisConceptsPatient-incurred costsTuberculosis servicesConventional cost-effectiveness thresholdsHigh-burden countriesEnd TB StrategySubstantial health gainsNet cost savingsResource implicationsCost-effectiveness thresholdMost intervention approachesTB StrategyTuberculosis incidenceMost interventionsSocietal perspectiveHealth gainsIntervention mixMelinda Gates FoundationSubstantial healthHealth effectsCurrent practiceExpansion of accessIntervention approachesEmpirical cost dataCost dataIntervention
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility